Akero’s NASH can­di­date re­duces liv­er fat in pa­tients tak­ing a GLP-1

Akero Ther­a­peu­tics said its NASH drug re­duced liv­er fat in pa­tients who were al­so tak­ing a GLP-1 ag­o­nist.

The NASH-fo­cused biotech on Mon­day re­leased topline da­ta from a Phase IIb tri­al for 32 pa­tients with type 2 di­a­betes and F1-F3 liv­er fi­bro­sis due to NASH who par­tic­i­pat­ed in the SYM­ME­TRY study for 12 weeks. Liv­er fi­bro­sis is scored based on how pro­gres­sive it is; F1 fi­bro­sis is in­dica­tive of min­i­mal scar­ring, while F3 is typ­i­cal­ly seen as se­vere.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER